

FIG. 1




FIG. 2




FIG. 3





FIG. 4



Healthy volunteers received single oral dose of Compound 1
(n = 9, 6 active / 3 placebo in each cohort)

FIG. 5a

Placebo




FIG. 5b.

Compound 1 30 mg




FIG. 5c.




FIG. 6a.

Placebo




FIG. 6b.

Compound 1 30 mg




FIG. 6c.





FIG. 7



Steady state concentration-time profile





FIG. 8a.




FIG. 8b.




FIG. 8c.




FIG. 9a.




FIG. 9b.




FIG. 9c.




FIG. 9d.




FIG. 10a.




FIG. 10b.




FIG. 10c.

Compound 1 60 mg QD




FIG. 10d.

Compound 1 120 mg QD

